У нас вы можете посмотреть бесплатно ATOMIC-Meso: pegargiminase in malignant pleural mesothelioma или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, discusses findings from the Phase II/III ATOMIC-Meso trial (NCT02709512) of pegargiminase with chemotherapy in patients with non-epithelioid pleural mesothelioma. Patients were randomized to receive either pegargiminase or placebo with chemotherapy, and overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints respectively. Both the endpoints were successfully met, and an encouraging safety profile was additionally reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.